Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E, Cahalin, Paul, Clark, Richard E, Hills, Robert K, Russell, Nigel H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165825/
https://www.ncbi.nlm.nih.gov/pubmed/29976746
http://dx.doi.org/10.3324/haematol.2018.189514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165825/
https://www.ncbi.nlm.nih.gov/pubmed/29976746
http://dx.doi.org/10.3324/haematol.2018.189514

Ejemplares similares